Deleted Tweets From Scott Gottlieb, R-D.C.
Scott Gottlieb's accounts: SteveFDA
Tracked Between: October 20, 2017-January 20, 2021
SteveFDA (R-D.C.)
@SGottliebFDA
At #FDA we’re advancing new approaches to developing drugs like master protocols, basket trials, and seamless trial designs as a way to promote innovation, reduce development costs, expand access, and make it more efficient for second to market innovations to reach patients.
SteveFDA (R-D.C.)
@SGottliebFDA
By reducing the cost of discovery and making the development process more efficient, we can make it easier to expand competition even in smaller markets where drugs target rare diseases and treat a limited numbers of patients. These categories can sustain multiple competitors.
SteveFDA (R-D.C.)
@SGottliebFDA
When innovators make discovery they enjoy a monopoly to that advance, but other scientists may be pursuing similar targets with their own novel compounds. The barriers to this second to market innovation influence how much therapeutic variety and competition we have for patients
SteveFDA (R-D.C.)
@SGottliebFDA
RT @CDCDirector: Honored to visit @US_FDA this week for a great conversation w. @SGottliebFDA on how CDC & FDA work together to respond not… QT @US_FDA: Honored to host @CDCDirector, Dr. Robert Redfield, today for a discussion about the important collaboration our age… https://t.co/H7e2Ptrn9S)
SteveFDA (R-D.C.)
@SGottliebFDA
#FDA is providing more information on how drug manufacturers, repackagers, wholesale distributors, and dispensers should verify products within the supply chain during investigations or quarantine suspect products under Drug Supply Chain Security Act. https://t.co/QtUTyHXYci https://t.co/WF2yaKI38D
SteveFDA (R-D.C.)
@SGottliebFDA
As we look to protect patients, our continued focus is toward a closed supply chain system that will prevent the introduction of illegitimate products, better detect them and enable #FDA and stakeholders to rapidly respond when such products are found
SteveFDA (R-D.C.)
@SGottliebFDA
Data from various studies, including this one, underscore the disturbing trends of rising youth use and the importance of continuing to advance #FDA’s Youth Tobacco Prevention Plan, which includes efforts to educate kids about risks from these products https://t.co/xgWW4ZAmqr
SteveFDA (R-D.C.)
@SGottliebFDA
THREAD: A recent study in #JAMA of adolescents and young adults in California shows rapidly increasing use of e-cigarettes, and reports misperceptions and lack of knowledge about these products https://t.co/pD7BugufmI https://t.co/EuLKRhPYbv
SteveFDA (R-D.C.)
@SGottliebFDA
We’ll release additional data soon on kids use of tobacco. None of the metrics we're seeing are moving in the right direction in relation to e-cig use by kids. We can’t allow a new generation to become addicted to nicotine. We'll be taking new steps to help reverse these trends.
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAfood: #OUTBREAK over. As of 10/25/18, there are 44 illnesses (#Salmonella Enteritidis) associated with shell eggs from Gr… https://t.co/vFhKpytccx
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDATobacco: Many teens underestimate how easy it is to become addicted to nicotine. The younger teens start using tobacco the m… https://t.co/MUhgDiaOWd
SteveFDA (R-D.C.)
@SGottliebFDA
RT @HHSGov: The @US_FDA has approved a new antiviral flu treatment for patients 12 years of age and older.… https://t.co/LqXvaLSoN8
SteveFDA (R-D.C.)
@SGottliebFDA
RT @RonPiervincenzi: Q&A of Lauren Silvis (@ScottGottliebMD Chief of Staff) at @PwC and @healthspottr hosted #digitalhealth high l… https://t.co/ybj5xpoqqO
SteveFDA (R-D.C.)
@SGottliebFDA
RT @lisagualtieri: Excited to hear Lauren Silvis of @US_FDA on #DigitalHealth and what or isn't appropriate in patient-facing #mHealth… https://t.co/9YKC7l4wAD
SteveFDA (R-D.C.)
@SGottliebFDA
RT @MediaJerNYC: Sue Desmond Hellmann chats with Anna Abram @US_FDA on moving medicine forward (who would know better?) #prixgalien https://t.co/F4k2gLfscR
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: #FDAOncology draft guidance: Master Protocols – Efficient Clinical Trial Design Strategies to Expedite Development… https://t.co/LVLHCodlgw
SteveFDA (R-D.C.)
@SGottliebFDA
RT @FDAOncology: From our archives: #FDAOncology perspective: Evaluating Endpoints & Evidence in Era of Breakthrough Therapies… https://t.co/vDSuw1bD18
SteveFDA (R-D.C.)
@SGottliebFDA
RT @lisagualtieri: Yesterday was my best Twitter day ever! First @chrissyfarr retweeted my RecycleHealth post, then @SGottliebFDA retw… https://t.co/tBhsxz6iNE
SteveFDA (R-D.C.)
@SGottliebFDA
RT @DrMarcSiegel: My patients deserve to know what they’re paying for | TheHill @DrMarcSiegel @HHSGov @SecAzar @thehill … https://t.co/F28fcRjomd
SteveFDA (R-D.C.)
@SGottliebFDA
RT @statnews: “With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effec… https://t.co/DbKAKBJZyv